Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenicriviroc in Primary Sclerosing Cholangitis
NCT02653625Phase 2Completed
- Sponsor
- Tobira Therapeutics
- Start
- Mar 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cenicriviroc in Primary Sclerosing Cholangitis (PSC), sponsored by Tobira Therapeutics. Primary endpoint: Percentage Change From Baseline Through Week 24 in Serum Alkaline Phosphatase (ALP). Started Mar 2016; status: completed.
02
Drugs
cenicriviroc
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT02653625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02653625.